Dr. Weeks’ Comment: Oops… vaccinations worsen the situation when exposed to wild COVID… “Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.“
Why are the world’s top vaccine promoters, like Paul Offit and Peter Hotez, frantically warning us about the unique and frightening dangers inherent in developing a coronavirus vaccine?�
Scientists first attempted to develop coronavirus vaccines after China’s 2002 SARS-CoV outbreak. Teams of US & foreign scientists vaccinated animals with the four most promising vaccines. At first, the experiment seemed successful as all the animals developed a robust antibody response to coronavirus. However, when the scientists exposed the vaccinated animals to the wild virus, the results were horrifying. Vaccinated animals suffered hyper-immune responses including inflammation throughout their bodies terminating with fatal lung infections. Researchers had seen this same “enhanced immune response” during human testing of the failed RSV vaccine tests in the 1960s. Two children died.��
Offit, Hotez and even Anthony Fauci (in an unguarded moment), have warned that any new coronavirus vaccine could trigger lethal immune reactions when vaccinated people come in contact with the wild virus. Instead of proceeding with caution, Fauci has made the reckless choice to fast track vaccines, partially funded by Gates, without animal studies (that could provide early warning of runaway immune response). Gates is so worried about the danger that he says he won’t distribute his vaccines until governments agree to indemnify him against lawsuits. On Feb 4th 2020, when there were only 11 active CV cases in the USA, the U.S. quietly pushed through Federal regulations giving coronavirus vaccine makers full immunity from liability.
Are you willing to take the risk?
PLoS One. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20.
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Tseng CT1, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB.
Erratum in
- PLoS One. 2012;7(8). doi:10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492.
Abstract
BACKGROUND:
Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.
DESIGN:
Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated i.m. on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.
RESULTS:
All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.
CONCLUSIONS:
These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.